In the BioHarmony Drug Report Database
Crizotinib
Xalkori (crizotinib) is a small molecule pharmaceutical. Crizotinib was first approved as Xalkori on 2011-08-26. It is used to treat non-small-cell lung carcinoma in the USA. It has been approved in Europe to treat non-small-cell lung carcinoma. The pharmaceutical is active against ALK tyrosine kinase receptor. In addition, it is known to target hepatocyte growth factor receptor. Xalkori’s patents are valid until 2029-11-06 (FDA).
Trade Name
|
Xalkori |
|---|---|
Common Name
|
crizotinib |
ChEMBL ID
|
CHEMBL601719 |
Indication
|
non-small-cell lung carcinoma |
Drug Class
|
Tyrosine kinase inhibitors |
Image (chem structure or protein)